Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?Journal of the American College of Cardiology, 2015-06, Vol.65 (24), p.2638-2651 [Peer Reviewed Journal]American College of Cardiology Foundation ;2015 American College of Cardiology Foundation ;Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Jun 23, 2015 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2015.05.001 ;PMID: 26088304Full text available |
|
2 |
Material Type: Article
|
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsThe Lancet (British edition), 2019-01, Vol.393 (10166), p.31-39 [Peer Reviewed Journal]2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jan 5, 2019 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(18)32590-X ;PMID: 30424892Full text available |
|
3 |
Material Type: Article
|
Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trialsThe Lancet (British edition), 2014-08, Vol.384 (9943), p.599-606 [Peer Reviewed Journal]Elsevier Ltd ;2014 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2014 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Aug 16, 2014 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(14)61216-2 ;PMID: 25131979 ;CODEN: LANCAOFull text available |
|
4 |
Material Type: Article
|
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular EventsThe New England journal of medicine, 2015-04, Vol.372 (16), p.1500-1509 [Peer Reviewed Journal]Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1500858 ;PMID: 25773607Full text available |
|
5 |
Material Type: Article
|
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular DiseaseThe New England journal of medicine, 2022-11, Vol.387 (20), p.1855-1864 [Peer Reviewed Journal]Copyright © 2022 Massachusetts Medical Society. All rights reserved. ;Copyright © 2022 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2211023 ;PMID: 36342163Full text available |
|
6 |
Material Type: Article
|
Cognitive Function in a Randomized Trial of EvolocumabThe New England journal of medicine, 2017-08, Vol.377 (7), p.633-643 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;info:eu-repo/semantics/openAccess ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1701131 ;PMID: 28813214Full text available |
|
7 |
Material Type: Article
|
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes MellitusCirculation (New York, N.Y.), 2019-05, Vol.139 (22), p.2528-2536 [Peer Reviewed Journal]2019 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.119.040130 ;PMID: 30882238Full text available |
|
8 |
Material Type: Article
|
Inflammatory and Cholesterol Risk in the FOURIER TrialCirculation (New York, N.Y.), 2018-07, Vol.138 (2), p.131-140 [Peer Reviewed Journal]2018 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;2018 American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.118.034032 ;PMID: 29530884Full text available |
|
9 |
Material Type: Article
|
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: Executive SummaryJournal of the American College of Cardiology, 2014-12, Vol.64 (24), p.2645-2687 [Peer Reviewed Journal]American Heart Association, Inc., and the American College of Cardiology Foundation ;2014 American Heart Association, Inc., and the American College of Cardiology Foundation ;2015 INIST-CNRS ;Copyright Elsevier Limited Dec 23, 2014 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2014.09.016 ;CODEN: JACCDIFull text available |
|
10 |
Material Type: Article
|
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HFEuropean heart journal, 2021-09, Vol.42 (36), p.3727-3738 [Peer Reviewed Journal]The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. 2021 ;The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. ;ISSN: 0195-668X ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/ehab560 ;PMID: 34448003Full text available |
|
11 |
Material Type: Article
|
Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)The American heart journal, 2022-09, Vol.251, p.61-69 [Peer Reviewed Journal]2022 The Authors ;2022. The Authors ;ISSN: 0002-8703 ;EISSN: 1097-6744 ;DOI: 10.1016/j.ahj.2022.05.004Full text available |
|
12 |
Material Type: Article
|
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER TrialJournal of the American College of Cardiology, 2019-06, Vol.73 (23), p.2961-2970 [Peer Reviewed Journal]Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;2019. American College of Cardiology Foundation ;ISSN: 0735-1097 ;ISSN: 1558-3597 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2019.03.513 ;PMID: 31196453Full text available |
|
13 |
Material Type: Article
|
Effects of dapagliflozin in DAPA-HF according to background heart failure therapyEuropean heart journal, 2020-07, Vol.41 (25), p.2379-2392 [Peer Reviewed Journal]The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology. 2020 ;The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology. ;ISSN: 0195-668X ;ISSN: 1522-9645 ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/ehaa183 ;PMID: 32221582Full text available |
|
14 |
Material Type: Article
|
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysisThe Lancet (British edition), 2010-10, Vol.376 (9749), p.1312-1319 [Peer Reviewed Journal]Elsevier Ltd ;2010 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2010 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Oct 16-Oct 22, 2010 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(10)61273-1 ;PMID: 20801494 ;CODEN: LANCAOFull text available |
|
15 |
Material Type: Article
|
The China Acute Myocardial Infarction (CAMI) Registry: A National Long-term Registry-Research-Education Integrated Platform for Exploring Acute Myocardial Infarction in ChinaThe American heart journal, 2016-05, Vol.175, p.193-201.e3 [Peer Reviewed Journal]2015 The Authors ;Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited May 2016 ;ISSN: 0002-8703 ;EISSN: 1097-6744 ;DOI: 10.1016/j.ahj.2015.04.014 ;PMID: 27179740 ;CODEN: AHJOA2Full text available |
|
16 |
Material Type: Article
|
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]Journal of lipid research, 2016-06, Vol.57 (6), p.1086-1096 [Peer Reviewed Journal]2016 © 2016 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology. ;Copyright © 2016 by the American Society for Biochemistry and Molecular Biology, Inc. ;Copyright © 2016 by the American Society for Biochemistry and Molecular Biology, Inc. 2016 ;ISSN: 0022-2275 ;EISSN: 1539-7262 ;DOI: 10.1194/jlr.P065334 ;PMID: 27102113Full text available |
|
17 |
Material Type: Article
|
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trialThe American heart journal, 2016-03, Vol.173, p.94-101 [Peer Reviewed Journal]Mosby, Inc. ;2015 Elsevier Inc. ;Copyright © 2015 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Mar 1, 2016 ;ISSN: 0002-8703 ;EISSN: 1097-6744 ;DOI: 10.1016/j.ahj.2015.11.015 ;PMID: 26920601Full text available |
|
18 |
Material Type: Article
|
Myocardial infarction accelerates atherosclerosisNature (London), 2012-07, Vol.487 (7407), p.325-329 [Peer Reviewed Journal]2015 INIST-CNRS ;COPYRIGHT 2012 Nature Publishing Group ;COPYRIGHT 2012 Nature Publishing Group ;Copyright Nature Publishing Group Jul 19, 2012 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/nature11260 ;PMID: 22763456 ;CODEN: NATUASFull text available |
|
19 |
Material Type: Article
|
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)Journal of the American College of Cardiology, 2014-04, Vol.63 (13), p.1278-1288 [Peer Reviewed Journal]American College of Cardiology Foundation ;2014 American College of Cardiology Foundation ;Copyright Elsevier Limited Apr 8, 2014 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2014.01.006Full text available |
|
20 |
Material Type: Article
|
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 TrialThe American heart journal, 2018-06, Vol.200, p.83-89 [Peer Reviewed Journal]2018 Elsevier Inc. ;Copyright © 2018 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Jun 2018 ;ISSN: 0002-8703 ;EISSN: 1097-6744 ;DOI: 10.1016/j.ahj.2018.01.012 ;PMID: 29898853Full text available |